Clinical Trial

Nefecon and Ambrisentan in IgA Nephropathy

Study acronym: BAIN
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and delaying eGFR progression, and observing changes in serum Gd-IgA1 levels
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-20; most recent amendment 2025-09-09.
Status change: Not Yet Recruiting → Recruiting 2025-09-09
Trial Details
NCT Number NCT07030894
Lead Sponsor The First Hospital of Jilin University
Conditions IgA Nephropathy, Chronic Kidney Disease, Proteinuria
Enrollment 129 participants
Start Date 2025-09-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-15